In the study of Deb et al., it was found that epigallocatechin-3-gallate acid could increase H3K9/18 acetylation of matrix metalloproteinase-3 promoter region in human prostate cancer cells by downregulating EZH2 and histone H3K27, thereby reactivating TIMP3 gene expression [27]. The gene discussed is EZH2; the disease is prostate carcinoma.